title: Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study.
abstract: A group of 13 patients with acute myeloid leukaemia of differing disease status were treated with continuous intravenous infusion of high-dose recombinant interleukin-2 (rIL-2). There was up-regulation of the cellular cytotoxic functions in all these patients following the rIL-2 therapy, with increase in the natural killer (NK) activity, lectin-dependent cellular cytotoxicity, induction of cytotoxicity-linked cytoplasmic serine esterase and lymphocyte activation. However, the clinical response to rIL-2 in these patients was disappointing, especially in patients treated in frank relapse. Although 1 patient treated in early second relapse achieved a third complete remission, the duration of the remission was brief and lasted only 6 months. Adverse reactions among these patients were common. Whether or not lymphokine-activated killer cells are needed to improve the response rate over rIL-2 alone in these patients deserves further investigation.
authors.affiliation: Department of Haematology, University College Hospital, London, UK.
authors.forename: S H
authors.initials: SH
authors.lastname: Lim
authors.forename: A C
authors.initials: AC
authors.lastname: Newland
authors.forename: S
authors.initials: S
authors.lastname: Kelsey
authors.forename: A
authors.initials: A
authors.lastname: Bell
authors.forename: E
authors.initials: E
authors.lastname: Offerman
authors.forename: C
authors.initials: C
authors.lastname: Rist
authors.forename: D
authors.initials: D
authors.lastname: Gozzard
authors.forename: D
authors.initials: D
authors.lastname: Bareford
authors.forename: M P
authors.initials: MP
authors.lastname: Smith
authors.forename: A H
authors.initials: AH
authors.lastname: Goldstone
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D005334:Fever / Q000209:etiology; D006402:Hematologic Diseases / Q000209:etiology; D006801:Humans; D007008:Hypokalemia / Q000209:etiology; D007022:Hypotension / Q000209:etiology; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D007376:Interleukin-2; D011994:Recombinant Proteins